Viruses TRIZ Cases
- Humanized Chimeric Notch Receptors for Low-Immunogenic Gene Control
Human HNF1-p65 transcription factors replace GAL4-VP16 in chimeric Notch receptors to reduce immunogenicity while preserving targeted gene expression.
- CMV Virus-Like Particle Platform With Universal Th Epitopes
Universal Th cell epitopes added to CMV VLPs boost helper T-cell activation and more consistent antibody responses, including in older adults.
- Micro-Dystrophin AAV Vectors With Genotype-Guided DMD Selection
Genotype-guided micro-dystrophin AAV therapy improves DMD patient selection while boosting muscle expression and limiting fibrosis.
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
Engineered NK-92 cells combine CAR, homing receptor, Fc receptor, and cytokine functions to improve tumor targeting and activity in suppressive microenvironments.
- Targeted Nucleic Acid Nanocarriers for Selective Stem Cell Editing
Targeted nanocarriers deliver transient gene editors to hematopoietic stem cells, avoiding viral complexity, cell sorting, and viability loss.
- Variant CD80 Immunomodulatory Proteins for Selective Immune Synapse Binding
Targeted CD80 amino acid changes improve selective binding to CD28, PD-L1, and CTLA-4 for stronger immune modulation.
- AAV GBA Gene Therapy for Parkinson's Lysosomal Dysfunction
AAV-delivered GBA and PD-associated gene constructs target lysosomal dysfunction and α-synuclein to address refractory Parkinson's symptoms.
- Targeted Nucleic Acid Nanocarriers for Hit-and-Run Cell Programming
Targeted nucleic acid nanocarriers enable transient expression in hematopoietic stem cells to create lasting therapeutic changes without viral delivery.
- Anti-VEGF AAV Expression Cassette for Sustained Ocular Therapy
Sequence optimization in an anti-VEGF rAAV cassette boosts expression for longer-lasting therapy with less immune response and irritation.
- PSCA-Targeted CAR Architecture for Selective Prostate Tumor Killing
A PSCA-specific CAR uses tuned costimulation and an IgG4 Fc spacer to kill prostate tumors while limiting off-target activity and cytokine release.
- Tumor Labeling Polypeptides for CAR-T Targeting in Solid Tumors
Artificial tumor-surface epitopes give CAR-modified immune cells a uniform target, improving solid tumor recognition while limiting off-target toxicity.
- CD33 DARIC and CAR Architecture for Controlled T Cell Signaling
Chemically regulated CD33 DARIC and CAR designs improve T cell persistence and control signaling to reduce toxicity and antigen-independent activation.
- Engineered Extracellular Vesicles for Stronger Vaccine Immune Response
Engineered extracellular vesicles combine antigens, adjuvants, and targeting moieties to boost vaccine immune response and clinical efficacy.